Vinva Investment Management Ltd Reduces Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Vinva Investment Management Ltd trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,064 shares of the company’s stock after selling 30,656 shares during the period. Vinva Investment Management Ltd’s holdings in Teva Pharmaceutical Industries were worth $4,175,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Atria Investments Inc lifted its position in shares of Teva Pharmaceutical Industries by 135.4% during the 3rd quarter. Atria Investments Inc now owns 30,856 shares of the company’s stock valued at $556,000 after buying an additional 17,746 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of Teva Pharmaceutical Industries by 68.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 32,402 shares of the company’s stock valued at $584,000 after buying an additional 13,215 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Teva Pharmaceutical Industries by 5.7% during the 3rd quarter. CIBC Asset Management Inc now owns 105,463 shares of the company’s stock valued at $1,900,000 after buying an additional 5,713 shares in the last quarter. Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $227,000. Finally, Thrivent Financial for Lutherans lifted its position in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after buying an additional 40,218 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of analyst reports. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.29 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The stock’s 50 day simple moving average is $17.99 and its two-hundred day simple moving average is $18.25. The company has a market cap of $18.46 billion, a price-to-earnings ratio of -11.23, a PEG ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.